Safety and immunogenicity of an AS03-adjuvanted plant-based SARS-CoV-2 vaccine in Adults with and without Comorbidities

The rapid spread of SARS-CoV-2 continues to impact humanity on a global scale with rising total morbidity and mortality. Despite the development of several effective vaccines, new products are needed to supply ongoing demand and to fight variants. We report herein a pre-specified interim analysis of...

Descripción completa

Detalles Bibliográficos
Autores principales: Charland, Nathalie, Gobeil, Philipe, Pillet, Stéphane, Boulay, Iohann, Séguin, Annie, Makarkov, Alexander, Heizer, Gretchen, Bhutada, Kapil, Mahmood, Asif, Trépanier, Sonia, Hager, Karen, Jiang-Wright, Julia, Atkins, Judith, Saxena, Pooja, Cheng, Matthew P., Vinh, Donald C., Boutet, Philippe, Roman, François, Van Der Most, Robbert, Ceregido, Maria Angeles, Dionne, Marc, Tellier, Guy, Gauthier, Jean-Sébastien, Essink, Brandon, Libman, Michael, Haffizulla, Jason, Fréchette, André, D’Aoust, Marc-André, Landry, Nathalie, Ward, Brian J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9646261/
https://www.ncbi.nlm.nih.gov/pubmed/36351931
http://dx.doi.org/10.1038/s41541-022-00561-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9646261/
https://www.ncbi.nlm.nih.gov/pubmed/36351931
http://dx.doi.org/10.1038/s41541-022-00561-2

Ejemplares similares